Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give Humacyte a consensus "Moderate Buy" rating (7 buys, 1 sell) with an average 12‑month price target of $8.29, far above the current share price.
• Shares trade around $1.07 (market cap ~$200M) with a negative PE (-4.65), an expected FY EPS of -1.27, and a 52‑week range of $1.04–$5.66.
• Humacyte is a clinical-stage biotechnology developer of off‑the‑shelf human acellular vessels (HAVs); institutional investors own ~44.7% of the stock, including a recent ~ $5.65M stake by RA Capital.

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $8.2857.

Several equities analysts have commented on the stock. HC Wainwright reissued a "buy" rating and set a $3.00 target price on shares of Humacyte in a research note on Monday, December 1st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Humacyte in a report on Monday, December 22nd. Benchmark dropped their target price on Humacyte from $14.00 to $11.00 and set a "buy" rating on the stock in a report on Thursday, November 13th. D. Boral Capital restated a "buy" rating and issued a $25.00 target price on shares of Humacyte in a research report on Monday, December 22nd. Finally, UBS Group reaffirmed a "buy" rating on shares of Humacyte in a research note on Monday, December 1st.

Humacyte Trading Down 0.9%

Shares of HUMA stock opened at $1.07 on Monday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.90 and a current ratio of 1.62. Humacyte has a 1 year low of $1.04 and a 1 year high of $5.66. The stock has a fifty day moving average of $1.33 and a two-hundred day moving average of $1.75. The firm has a market capitalization of $200.38 million, a PE ratio of -4.65 and a beta of 1.90.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.03. The business had revenue of $0.75 million for the quarter, compared to analyst estimates of $0.92 million. As a group, research analysts expect that Humacyte will post -1.27 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Nuveen LLC acquired a new stake in Humacyte in the 1st quarter valued at about $502,000. Wellington Management Group LLP raised its holdings in shares of Humacyte by 22.0% in the 1st quarter. Wellington Management Group LLP now owns 310,777 shares of the company's stock worth $530,000 after purchasing an additional 56,042 shares in the last quarter. Walleye Capital LLC lifted its stake in Humacyte by 41.3% during the first quarter. Walleye Capital LLC now owns 150,762 shares of the company's stock valued at $257,000 after purchasing an additional 44,064 shares during the last quarter. MetLife Investment Management LLC lifted its stake in Humacyte by 14.4% during the first quarter. MetLife Investment Management LLC now owns 51,442 shares of the company's stock valued at $88,000 after purchasing an additional 6,482 shares during the last quarter. Finally, RA Capital Management L.P. bought a new stake in Humacyte during the first quarter worth approximately $5,648,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company's proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient's own tissue. Humacyte's primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company's lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.